Pirtobrutinib Gains First-Line Nod for CLL/SLL

MedscapeView source article

Part of story

FDA approves Lilly's Jaypirca as first-line CLL therapy

The FDA approved pirtobrutinib (Jaypirca, Eli Lilly) for adults with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma with no known 17p deletion.

Oct 5, 20262 sourcesCancer treatment breakthroughs Eli Lilly

FDA approves Lilly's Jaypirca as first-line CLL therapy

Other sources for this story

STAT News

Pirtobrutinib Gains First-Line Nod for CLL/SLL

Part of story

FDA approves Lilly's Jaypirca as first-line CLL therapy

Other sources for this story

Lilly's Jaypirca approved as first-line CLL therapy

Pirtobrutinib Gains First-Line Nod for CLL/SLL

Part of story

FDA approves Lilly's Jaypirca as first-line CLL therapy

Other sources for this story

Lilly's Jaypirca approved as first-line CLL therapy